Skip to main content

ImageneBio, Inc.

IMA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001835579

In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $17.3K in total
1
13F holdersQ2 2026, −4 vs. previous quarter
35
13F valueReported value at the end of Q2 2026
$36.8M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding IMA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding IMA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by ImageneBio, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 20, 2026 (view filing)9:47 PM ETJul 16-174 daysLally Robert BPrincipal Accounting OfficerSSale−3.20K$5.42−$17.3K−5.4%55.6K after2 lots
Apr 16, 2026 (view filing)7:23 PM ETApr 142 daysOrbiMed Advisors LLC and 2 othersDirectorPPurchase+721.3K–––384.7K afterDerivative2 lotsDuplicate filing
Apr 16, 2026 (view filing)Apr 142 daysBonita David PDirectorPPurchase+721.3K–––384.7K afterDerivative2 lots
Dec 29, 2025 (view filing)Dec 245 daysSlattery Joseph PDirectorPPurchase+16.0K$5.99+$95.8KNew position16.0K after
Jul 30, 2025 (view filing)Jul 255 daysLateBonita David PDirectorPPurchase+83.6K$29.90+$2.50M+40.9%287.9K after
Jul 30, 2025 (view filing)Jul 255 daysLateStampacchia OtelloDirectorPPurchase+267.6K$29.90+$8.00M+142.8%455.0K after
Jun 24, 2022 (view filing)5:39 PM ETJun 22-242 daysOrbiMed Advisors LLC and 2 othersDirectorPPurchase−252.2K$4.47−$1.13M−10.7%2.10M after4 lotsDuplicate filing
Jun 24, 2022 (view filing)Jun 22-242 daysBonita David PDirectorPPurchase−252.2K$4.47−$1.13M−10.7%2.10M after4 lots
Jan 12, 2022 (view filing)Jan 10-112 daysZhang Xiaoyan MichelleChief Scientific OfficerSSale−1.00K$12.00−$12.0K−2.2%44.5K after2 lots
Dec 14, 2021 (view filing)8:27 PM ETMar 30259 daysLateAtlas Venture Fund XI, L.P. and 5 others10% OwnerPPurchase+125.0K$16.00+$2.00M+16.7%874.6K afterDuplicate filing

Top 10 13F holders, Q2 2026

The largest institutional positions in ImageneBio, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 35 holders
Institutions holding IMA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BVF Inc1,110,002$6.55M0.17%00.0%Unchanged
Blue Owl Capital Holdings LP917,692$5.41M0.82%−41,645−4.3%Reduced
OrbiMed Advisors LLC909,269$5.36M0.10%+530,713+140.2%Added
Cable Car Capital LLC781,599$4.61M0.10%+26,850+3.6%Added
Omega Fund Management, LLC455,361$2.69M1.45%00.0%Unchanged
RTW Investments, LP334,445$1.97M0.02%00.0%Unchanged
Vanguard Capital Management LLC320,518$1.89M0.00%−4,637−1.4%Reduced
Trails Edge Capital Partners, LP282,004$1.66M0.26%+282,004New
BML Capital Management, LLC200,730$1.18M0.68%00.0%Unchanged
Monashee Investment Management LLC192,344$1.13M1.90%+192,344New